Vaccine Successful in First Trials

A Swedish HIV vaccine study conducted by researchers at Karolinska Institutet (KI), Karolinska University Hospital and the Swedish Institute for Infectious Disease Control (SMI) has produced surprisingly good results. "Never has such a good result been seen with a vaccine of this type," says Professor Eric Sandström, Chief Physician at Karolinska University Hospital.

A vaccine developed by SMI scientists has now undergone the first clinical study on healthy individuals in Sweden in order to examine its safety and different methods of administration. The vaccine is what is known as a genetic vaccine, which uses parts of the virus DNA to stimulate the rapid endogenous production of the proteins for which the injected DNA codes.

The trial subjects were vaccinated on three occasions with this vaccine using a needle-free method of injection. In order to enhance the effect, the researchers also gave the subjects a fourth dose of a vaccine in which parts of the HIV virus DNA had been integrated into another virus (vaccinia = the cowpox virus).

"Our vaccine is designed in such a way that it's able to protect against many of the circulating HIV types in Africa and the West," says Professor Britta Wahren at the SMI/KI. Over 90 per cent of the trial subjects developed an immune response to HIV, and the vaccines have been tolerated well.

Scientists now hope to follow up the Swedish study with a larger phase 1 – phase 2 study in Tanzania, planned to commence this autumn, in order to corroborate the Swedish results on African subjects and to help train Tanzanians to carry out parts of the study, including sophisticated laboratory examinations, on site.